Explore how the U.S. prospective most-favored-nation (MFN) pricing strategy aims to lower drug prices while preserving pharmaceutical innovation and encouraging fair global contributions to R&D funding.
Recent legislative changes to Medicare’s drug price negotiation program expand orphan drug exclusions, delaying price negotiation for expensive specialty drugs and increasing costs for Medicare beneficiaries.
IQVIA study reveals Medicare Part D plans frequently deny initial access to medications for chronic conditions, highlighting payer policy and compliance challenges.
The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.
